Re-exploring Tumor Necrosis Factor Alpha as a Target for Therapy in Intracerebral Hemorrhage

Reza Behrouz

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Intracerebral hemorrhage (ICH) is a perplexing condition with high mortality and no treatment beyond supportive care. A major portion of the injurious process is takes place during the hours following the development of hematoma. This so-called secondary injury is characterized by an inflammatory cascade that involves a variety of cytokines, including tumor necrosis factor (TNF)-α. Several studies in the rodent model of ICH have shown a rapid increase in brain concentrations of TNF-α following hematoma induction. There is a reasonable body of evidence from experimental models of ICH suggesting that upregulation of TNF-α adjacent to the hematoma is associated with increased peri-hematomal edema, and that inhibition of TNF-α attenuates the formation and progression of this edema and ultimately improves outcomes. Unfortunately, efforts to expand upon these findings have interminably stalled at the pre-clinical phase. A robust clinical study to validate serum TNF-α as a marker for secondary injury in ICH patients is yet to materialize.

Original languageEnglish (US)
Pages (from-to)93-96
Number of pages4
JournalTranslational Stroke Research
Volume7
Issue number2
DOIs
StatePublished - Apr 1 2016

Fingerprint

Cerebral Hemorrhage
Tumor Necrosis Factor-alpha
Hematoma
Edema
Therapeutics
Wounds and Injuries
Rodentia
Theoretical Models
Up-Regulation
Cytokines
Mortality
Brain
Serum

Keywords

  • Biomarkers
  • Inflammation
  • Intracerebral hemorrhage
  • Secondary brain injury
  • Tumor necrosis factor alpha

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Re-exploring Tumor Necrosis Factor Alpha as a Target for Therapy in Intracerebral Hemorrhage. / Behrouz, Reza.

In: Translational Stroke Research, Vol. 7, No. 2, 01.04.2016, p. 93-96.

Research output: Contribution to journalArticle

@article{fa942949741746fa99e7ae78298b28ce,
title = "Re-exploring Tumor Necrosis Factor Alpha as a Target for Therapy in Intracerebral Hemorrhage",
abstract = "Intracerebral hemorrhage (ICH) is a perplexing condition with high mortality and no treatment beyond supportive care. A major portion of the injurious process is takes place during the hours following the development of hematoma. This so-called secondary injury is characterized by an inflammatory cascade that involves a variety of cytokines, including tumor necrosis factor (TNF)-α. Several studies in the rodent model of ICH have shown a rapid increase in brain concentrations of TNF-α following hematoma induction. There is a reasonable body of evidence from experimental models of ICH suggesting that upregulation of TNF-α adjacent to the hematoma is associated with increased peri-hematomal edema, and that inhibition of TNF-α attenuates the formation and progression of this edema and ultimately improves outcomes. Unfortunately, efforts to expand upon these findings have interminably stalled at the pre-clinical phase. A robust clinical study to validate serum TNF-α as a marker for secondary injury in ICH patients is yet to materialize.",
keywords = "Biomarkers, Inflammation, Intracerebral hemorrhage, Secondary brain injury, Tumor necrosis factor alpha",
author = "Reza Behrouz",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/s12975-016-0446-x",
language = "English (US)",
volume = "7",
pages = "93--96",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "2",

}

TY - JOUR

T1 - Re-exploring Tumor Necrosis Factor Alpha as a Target for Therapy in Intracerebral Hemorrhage

AU - Behrouz, Reza

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Intracerebral hemorrhage (ICH) is a perplexing condition with high mortality and no treatment beyond supportive care. A major portion of the injurious process is takes place during the hours following the development of hematoma. This so-called secondary injury is characterized by an inflammatory cascade that involves a variety of cytokines, including tumor necrosis factor (TNF)-α. Several studies in the rodent model of ICH have shown a rapid increase in brain concentrations of TNF-α following hematoma induction. There is a reasonable body of evidence from experimental models of ICH suggesting that upregulation of TNF-α adjacent to the hematoma is associated with increased peri-hematomal edema, and that inhibition of TNF-α attenuates the formation and progression of this edema and ultimately improves outcomes. Unfortunately, efforts to expand upon these findings have interminably stalled at the pre-clinical phase. A robust clinical study to validate serum TNF-α as a marker for secondary injury in ICH patients is yet to materialize.

AB - Intracerebral hemorrhage (ICH) is a perplexing condition with high mortality and no treatment beyond supportive care. A major portion of the injurious process is takes place during the hours following the development of hematoma. This so-called secondary injury is characterized by an inflammatory cascade that involves a variety of cytokines, including tumor necrosis factor (TNF)-α. Several studies in the rodent model of ICH have shown a rapid increase in brain concentrations of TNF-α following hematoma induction. There is a reasonable body of evidence from experimental models of ICH suggesting that upregulation of TNF-α adjacent to the hematoma is associated with increased peri-hematomal edema, and that inhibition of TNF-α attenuates the formation and progression of this edema and ultimately improves outcomes. Unfortunately, efforts to expand upon these findings have interminably stalled at the pre-clinical phase. A robust clinical study to validate serum TNF-α as a marker for secondary injury in ICH patients is yet to materialize.

KW - Biomarkers

KW - Inflammation

KW - Intracerebral hemorrhage

KW - Secondary brain injury

KW - Tumor necrosis factor alpha

UR - http://www.scopus.com/inward/record.url?scp=84959558672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959558672&partnerID=8YFLogxK

U2 - 10.1007/s12975-016-0446-x

DO - 10.1007/s12975-016-0446-x

M3 - Article

C2 - 26762364

AN - SCOPUS:84959558672

VL - 7

SP - 93

EP - 96

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 2

ER -